Patient and Payer Considerations in Parkinson Disease Psychosis to Optimize Population Health Outcomes: A Multistakeholder Panel Discussion

Author(s)Maria Lopes, MD, MS, Fernando L. Pagan, MD, Bhavesh Shah, RPh, BCOP

This publication was sponsored by Acadia Pharmaceuticals Inc.

This clinical brief provides insights from a panel of stakeholders about Parkinson disease (PD) and the prevalence and care of PD psychosis (PDP). The experts also offer key information about PDP from the payer and clinical perspectives.

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Patient and Payer Considerations in Parkinson Disease Psychosis to Optimize Population Health Outcomes: A Multistakeholder Panel Discussion

Trending on AJMC

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

ATTR-CM Incidence, Prevalence Rose Sharply in the US

Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

FDA Approves Palbociclib for HR+, HER2+ Breast Cancer Maintenance

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Patient and Payer Considerations in Parkinson Disease Psychosis to Optimize Population Health Outcomes: A Multistakeholder Panel Discussion

Trending on AJMC

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

ATTR-CM Incidence, Prevalence Rose Sharply in the US

Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

FDA Approves Palbociclib for HR+, HER2+ Breast Cancer Maintenance